Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Approval Alert: Biocon’s Biosimilar Bevacizumab FDA-Approved

Apr 10, 2025

On 10 April 2025, Biocon Biologics announced that the FDA has approved its Jobevne™ (bevacizumab-nwgd), biosimilar to Roche/Genentech’s Avastin® (bevacizumab) for intravenous use in treating various cancers including metastatic renal cell carcinoma, metastatic colorectal cancer and cervical cancer.

The first bevacizumab biosimilar approved in the US was Amgen’s Mvasi® in September 2017.  There are currently four other bevacizumab biosimilars included in the FDA’s approved drugs database: Amneal’s Alymsys® (April 2022), Bio-Thera/Sandoz’s Avzivi® (December 2023), Celltrion’s Vegzelma™ (September 2022) and Pfizer’s Zirabev® (June 2019).